Overview

2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

Status:
Completed
Trial end date:
2019-11-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of inflammation and pain associated with cataract surgery.
Phase:
Phase 3
Details
Lead Sponsor:
InSite Vision
Sun Pharma Global FZE
Treatments:
Dexamethasone